5-MeO-DMT for Veterans

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans

This open-label study (n=86) examined the effectiveness of psychedelic-assisted therapy (PAT) among trauma-exposed Special Operations Forces Veterans (SOFV) in Mexico. Results indicated significant improvements in self-reported PTSD symptoms, depression, anxiety, insomnia severity, post-concussive symptoms, satisfaction with life, psychological flexibility, and cognitive functioning from baseline to one-month follow-up. The combination of ibogaine and 5-MeO-DMT assisted therapy showed potential for providing rapid and lasting improvements in mental health functioning, with effects observed up to six months after treatment.

Published: September 21, 2023
Journal: The American Journal of Drug and Alcohol Abuse
Authors: Davis, A. K., Xin, Y., Sepeda, N. D., Averill, L. A.

Paywallindividual

Predictors of psychedelic treatment outcomes among special operations forces veterans

This prospective study (n=86) examined the effects of ibogaine and 5-MeO-DMT treatment on U.S. Special Operations Forces Veterans with trauma exposure. Younger age and higher baseline levels of depression and anxiety were correlated with significant improvements in mental and psychosocial outcomes from baseline to 1-month follow-up. Greater intensity of changes in consciousness was linked to improved long-term mental health and psychosocial outcomes up to 6 months post-treatment.

Published: September 7, 2023
Journal: Psychology of Consciousness Theory Research and Practice
Authors: Xin, Y., Armstrong, S. B., Averill, L. A., Sepeda, N. D., Davis, A. K.

Open Accessindividual

Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans

This prospective study (n=86) evaluated the effects of ibogaine & 5-MeO-DMT treatment on risky alcohol use & PTSD symptoms among US Special Operations Forces Veterans. It found a significant reduction in alcohol use from pre-treatment to 1-month, 3-months, and 6-months post-treatment, and large differences between responders and non-responders in PTSD symptom and cognitive functioning change, suggesting that psychedelic-assisted therapy may hold promise for individuals with complex trauma and alcohol misuse.

Published: February 1, 2023
Journal: Military Medicine
Authors: Armstrong, S. B., Xin, Y., Sepeda, N. D., Polanco, M., Averill, L. A., Davis, A. K.

Open Accessindividual

Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans

In a retrospective survey of 27 US Special Operations Forces veterans who completed a psychedelic treatment programme in Mexico, self‑reported alcohol misuse and post‑traumatic stress symptoms showed marked reductions with very large effect sizes (d≈–2.4 to –2.8) and 85% reduced drinking to non‑risky levels, while psychological flexibility increased. The uncontrolled, retrospective design limits causal inference, and the authors call for rigorous longitudinal trials to determine whether psychedelic‑assisted therapy is effective in this population.

Published: February 1, 2022
Journal: Journal of Psychedelic Studies
Authors: Mangini, P., Averill, L. A., Davis, A. K.

Open Accessindividual

Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans

In a retrospective survey of 51 U.S. Special Operations Forces veterans who completed a psychedelic programme in Mexico (ibogaine and 5‑MeO‑DMT), participants reported very large reductions in suicidal ideation, PTSD, depression, anxiety and cognitive impairment alongside large increases in psychological flexibility. These preliminary, self‑reported findings are limited by retrospective design and lack of randomisation/blinding, so controlled trials are needed to establish efficacy.

Published: July 8, 2020
Journal: Chronic Stress
Authors: Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., Amoroso, T.

Paywallindividual

A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder

This case report SPECT imaging study explored the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder (AUD). It reported that the patient felt improvement in mood, cessation of alcohol use, and decreased cravings at 5 days post-treatment, but the patient returned partially to mild alcohol use at 2 months. Also, higher perfusion in multiple brain regions broadly associated with AUD and known pharmacology of both compounds was reported.

Published: January 1, 2018
Journal: Progress in Brain Research
Authors: Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi #, B., Calvey, T.

Company

Product

Legal

5-MeO-DMT

Veterans

Academic Research

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans

Predictors of psychedelic treatment outcomes among special operations forces veterans

Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans

Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans

Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans

A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder

Clinical Trials

Explore further